Gadisseux J F, Fournaux J, Hallet J, Ferriere G
Acta Neurol Belg. 1982 Nov-Dec;82(6):327-38.
Thirty-three patients showing a definite group of symptoms including chiefly agitation or self-mutilation often dramatic have been treated with sultopride at doses ranging from 7 to 50 mg/kg/day at the Institut Médico-Pédagogique de l'Enfant-Jésus at Ciney. Forty-eight per cent showing this particular symptoms have been cured or greatly improved with sultopride. In 36% the response was incomplete in that it appeared to be identical with sultopride solely or with the previous medications. An opposite result has been noted in 16% only. Side-effects consisted in extra-pyramidal symptoms, drowsiness and digestive disorders. This study leads to the conclusion that sultopride can be considered as the most efficient therapeutical approach to the management of agitation or self-mutilation in severe encephalopathy.
在 Ciney 的耶稣儿童医学教育学院，对 33 例表现出明确症状群（主要包括激动或自残，症状通常较为显著）的患者使用舒托必利进行治疗，剂量范围为每日 7 至 50 毫克/千克。48% 表现出这种特定症状的患者经舒托必利治疗后已治愈或有显著改善。36% 的患者反应不完全，因为其反应似乎仅与舒托必利或先前用药相同。仅 16% 的患者出现相反结果。副作用包括锥体外系症状、嗜睡和消化系统紊乱。这项研究得出结论，舒托必利可被视为治疗严重脑病中激动或自残的最有效治疗方法。
